Low Field set-up for Magnetic Resonance Imaging

n/

Discovering extremely compact and metal-poor, star-forming dwarf galaxies out to z ~ 0.9 in the VIMOS Ultra-Deep Survey

We report the discovery of 31 low-luminosity (-14.5 > M_{AB}(B) > -18.8), extreme emission line galaxies (EELGs) at 0.2 < z < 0.9 identified by their unusually high rest-frame equivalent widths (100 < EW[OIII] < 1700 A) as part of the VIMOS Ultra Deep Survey (VUDS). VIMOS optical spectra of unprecedented sensitivity ($I_{AB}$ ~ 25 mag) along with multiwavelength photometry and HST imaging are used to investigate spectrophotometric properties of this unique sample and explore, for the first time, the very low stellar mass end (M* < 10^8 M$_{\odot}$) of the luminosity-metallicity (LZR) and mass-metallicity (MZR) relations at z < 1. Characterized by their extreme compactness (R50 < 1 kpc), low stellar mass and enhanced specific star formation rates (SFR/M* ~ 10^{-9} - 10^{-7} yr^{-1}), the VUDS EELGs are blue dwarf galaxies likely experiencing the first stages of a vigorous galaxy-wide starburst. Using T_e-sensitive direct and strong-line methods, we find that VUDS EELGs are low-metallicity (7.5 < 12+log(O/H) < 8.3) galaxies with high ionization conditions, including at least three EELGs showing HeII 4686A emission and four EELGs of extremely metal-poor (<10% solar) galaxies. The LZR and MZR followed by EELGs show relatively large scatter, being broadly consistent with the extrapolation toward low luminosity and mass from previous studies at similar redshift. However, we find evidences that galaxies with younger and more vigorous star formation -- as characterized by their larger EWs, ionization and sSFR -- tend to be more metal-poor at a given stellar mass.Comment: Letter in A&A 568, L8 (2014). This replacement matches the published versio

Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models

Cytotoxic chemotherapy is an effective treatment for invasive breast cancer. However, experimental studies in mice also suggest that chemotherapy has pro-metastatic effects. Primary tumours release extracellular vesicles (EVs), including exosomes, that can facilitate the seeding and growth of metastatic cancer cells in distant organs, but the effects of chemotherapy on tumour-derived EVs remain unclear. Here we show that two classes of cytotoxic drugs broadly employed in pre-operative (neoadjuvant) breast cancer therapy, taxanes and anthracyclines, elicit tumour-derived EVs with enhanced pro-metastatic capacity. Chemotherapy-elicited EVs are enriched in annexin A6 (ANXA6), a Ca2+-dependent protein that promotes NF-κB-dependent endothelial cell activation, Ccl2 induction and Ly6C+CCR2+ monocyte expansion in the pulmonary pre-metastatic niche to facilitate the establishment of lung metastasis. Genetic inactivation of Anxa6 in cancer cells or Ccr2 in host cells blunts the prometastatic effects of chemotherapy-elicited EVs. ANXA6 is detected, and potentially enriched, in the circulating EVs of breast cancer patients undergoing neoadjuvant chemotherapy